Hormonal Therapy is treatment that adds, blocks, or removes hormones. For certain conditions (such as diabetes or menopause), hormones are given to adjust low hormone levels. To slow or stop the growth of certain cancers (such as prostate and breast cancer), synthetic hormones or other drugs may be given to block the body’s natural hormones. Sometimes surgery is needed to remove the gland that makes a certain hormone. Also called endocrine therapy, hormone therapy, and hormone treatment.
Gender dysphoria manifests early in childhood and can persist for years before patients undergo counseling and treatment, a Cedars-Sinai study has found.
Menarini Silicon Biosystems, the pioneer of liquid biopsy and single cell technologies, announced today that results from a new study presented at the virtual 2020 meeting of the American Society of Clinical Oncology suggest that circulating tumor cell counts may be useful in determining long-term prognosis and guiding treatment selection in patients with metastatic castrate sensitive prostate cancer.
Up to now, women who present with a new diagnosis of breast cancer that is already in an advanced stage (stage IV) face an unanswered question about whether surgery and radiation to the tumor in the breast (local therapy) will prolong survival compared to the traditional treatment of systemic treatment alone.
Breast cancer patients do not have an increased risk of developing rheumatoid arthritis. A Swedish cohort study has now come to this conclusion.
Researchers from the Harvard Medical School and Brigham and Women's Hospital working in collaboration have found that tofu and other plant-based proteins contain certain nutrients called isoflavones that can help those with heart disease and lower their disease risk.
Eric Prossnitz, PhD, hopes to help many of the 12% of American women who are projected to be diagnosed with breast cancer in their lifetimes.
In the updated results from NRG Oncology/NSABP B-42 trial through 10 years of observation, extending letrozole therapy for additional five years after five years of adjuvant endocrine therapy resulted in a statistically significant improvement in the 10-year disease-free survival (DFS) of postmenopausal women with hormone-receptor-positive breast cancer.
Researchers from the Baylor College of Medicine and Harvard Medical School have found a novel mechanism to explain the resistance of certain breast cancers that spread in the major organs of the body. They hope that this would help develop new therapeutic strategies to treat the cancer.
Ductal carcinoma in-situ (DCIS) accounts for one-fifth of breast cancer cases in the United States, according to the American Cancer Society.
Researchers have managed to grow human, testosterone-producing cells, which could lead to improved treatment options for low testosterone levels.
October is Breast Cancer Awareness Month, an annual campaign to raise awareness about the potentially-fatal disease. Breast cancer is known as an illness that affects mostly women, but about 1 percent of all breast cancers affect men, too.
A new PARP-inhibitor has been shown to significantly delayed cancer progression among patients with prostate cancer who had cancer cells with faulty DNA repair genes.
A study led by UCLA researchers found that adding ribociclib, a targeted therapy drug, to standard hormone therapy has been shown to significantly improve overall survival in postmenopausal women with advanced hormone-receptor positive/HER2- breast cancer, one of the most common forms of the disease.
Breast cancer is one of the most aggressive types of cancers in the world. It is the commonest cause of cancer death in women worldwide, and it represented about 12 percent of all new cancer cases in 2012. Current predictions and statistics suggest that both worldwide incidence of breast cancer and related mortality are on the rise. Globally, breast cancer now represents one in four of all cancers in women.
Electromagnetic fields might help prevent some breast cancers from spreading to other parts of the body, new research has found.
A new portable device that utilizes artificial intelligence (AI) and biosensors can rapidly detect if cancer cells thrive after chemotherapy treatment.
There have been studies and anecdotal reports about worsening of sleep quality and increasing fatigue among women who are near menopause or have reached menopause.
Pelvic pain associated with endometriosis often becomes chronic and can persist (or recur) following surgical and hormonal interventions.
Adding the targeted therapy ribociclib to hormone therapy significantly improved overall survival (OS) in premenopausal patients with advanced hormone receptor-positive (HR+) breast cancer, according to results of the MONALEESA-7 Phase III clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.
Enzalutamide, an oral androgen receptor inhibitor, can improve outcomes for men with metastatic hormone-sensitive prostate cancer, according to a large study presented by Christopher Sweeney, MBBS of Dana-Farber Cancer Institute's Lank Center for Genitourinary Oncology, during the American Society of Clinical Oncology Annual Meeting.